Advertisement Pharmaceutical Business review -

Advertisement

Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 23, 2019

Cabotegravir, rilpivirine combo meets primary endpoint in HIV-1 phase 3 trial

ViiV Healthcare said that the injectable two-drug regimen of cabotegravir and rilpivirine succeeded in the ATLAS-2M phase 3 trial in adult patients with HIV-1 by meeting the primary endpoint.

Image: Cabotegravir, rilpivirine combo succeeds in ATLAS-2M phase 3 trial in HIV-1. Photo: courtesy of Darwin Laganzon/Pixabay.